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Abstract
Background: People who inject drugs (PWID) have increased risk of morbidity and mortality. We update and present
estimates and trends of the prevalence of current PWID and PWID subpopulations in 96 US metropolitan statistical areas
(MSAs) for 1992–2007. Current estimates of PWID and PWID subpopulations will help target services and help to understand
long-term health trends among PWID populations.
Methodology: We calculated the number of PWID in the US annually from 1992–2007 and apportioned estimates to MSAs
using multiplier methods. We used four types of data indicating drug injection to allocate national annual totals to MSAs,
creating four distinct series of component estimates of PWID in each MSA and year. The four component estimates are
averaged to create the best estimate of PWID for each MSA and year. We estimated PWID prevalence rates for three
subpopulations defined by gender, age, and race/ethnicity. We evaluated trends using multi-level polynomial models.
Results: PWID per 10,000 persons aged 15–64 years varied across MSAs from 31 to 345 in 1992 (median 104.4) to 34 to 324
in 2007 (median 91.5). Trend analysis indicates that this rate declined during the early period and then was relatively stable
in 2002–2007. Overall prevalence rates for non-Hispanic black PWID increased in 2005 as compared to other racial/ethnic
groups. Hispanic prevalence, in contrast, declined across time. Importantly, results show a worrisome trend in young PWID
prevalence since HAART was initiated – the mean prevalence was 90 to 100 per 10,000 youth in 1992–1996, but increased to
.120 PWID per 10,000 youth in 2006–2007.
Conclusions: Overall, PWID rates remained constant since 2002, but increased for two subpopulations: non-Hispanic black
PWID and young PWID. Estimates of PWID are important for planning and evaluating public health programs to reduce
harm among PWID and for understanding related trends in social and health outcomes.
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Introduction
Injection drug use continues to account for a substantial
proportion of new Human immunodeficiency virus (HIV)
diagnoses in the United States, and is the third most frequently
reported risk factor for HIV infection, after male-to-male sexual
contact and high-risk heterosexual contact [1,2]. Overall, people
who inject drugs (PWID) represented 9% of new HIV infections in
2009 and 17% of those living with HIV in 2008 [2,3]. Yet, the
most alarming feature of HIV among PWID in the U.S. is racial/
ethnic disparities. Disparities have been apparent in HIV among
PWID since early in the epidemic [4,5,6,7] and still are very
marked [1,8,9,10]. More than 50% of PWID living with a
diagnosis of HIV infection at the end of 2009 were non-Hispanic
black, 27% were Hispanic, and 21% were non-Hispanic white
[1,2,10]. Non-Hispanic blacks who inject drugs are ten times as
likely to be diagnosed with HIV as non-Hispanic white injectors
[8,9].
PWID are at high risk for HIV, hepatitis B and C, and many
socially related problems. PWID experience high rates of
morbidity and mortality, often from drug overdose, endocarditis,
cellulitis, and abscesses [11,12,13,14,15] – in addition to, increased
rates of exposure to violence and injury [16,17,18]. Further,
PWID experience poor health outcomes due to either lack of or
delayed access to effective treatment, continuation of illicit drug
use, and depression and negative life events [19,20,21,22,23,24].
Drug use patterns and prevalence reflect notable differences in
the U.S. [25,26,27]. U.S. figures, as reported by SAMHSA [27],
PLOS ONE | www.plosone.org 1 June 2013 | Volume 8 | Issue 6 | e64789
New York University (NYU), New York, New York, United States of America,
                                                                                                             ,               4America 
Disease        Control,     Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, Georgia, United States of America
Centers for Disease Control, Division of HIV/AIDS Prevention, Surveillance, Epidemiology and Laboratory Science, Atlanta, Georgia, United States of America,
                                         Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America7Department of Epidemiology,
of
for 2002–05 show injection was the primary route of administra-
tion for a higher proportion of heroin users (42%) than for
methamphetamine (9%), stimulant (5%) or cocaine users (3%).
Although difficult to ascertain, geographic-specific data over
time on PWID prevalence rates are important, as they may help
policy makers allocate resources and establish public policy to
reduce harm among PWID and PWID subpopulations [28,29,30].
Additionally, such data could provide a foundation for the design,
implementation and evaluation of structural interventions and
service coverage, such as the expansion of Opioid Treatment
Programs (OTPs) and Medication-Assisted Treatment (MAT)
facilities in areas of need [31,32,33]. Trend data on PWID
prevalence may help forecast which metropolitan areas may be at
greater risk for outbreaks of drug injecting and blood-borne
infections associated with drug injection. Data on PWID
populations also allows study of patterns of change of PWID
prevalence in relation to social, economic and political predictors
in metropolitan areas [32,33].
Drug use–particularly illicit and injection drug use –carries a
heavy stigma. PWID are near the bottom in terms of social
tolerance in the hierarchy of client groups [34,35], and most are
reluctant to divulge any illegal drug use or needle use. Thus,
despite the need for data on numbers of PWID, several factors
make it difficult to assess the actual number of PWID over time
and across U.S. geographic areas [36,37,38,39,40,41,42].
Historical Variation in PWID Prevalence and
Subpopulation Prevalence Rates Across Large U.S.
Metropolitan Statistical Areas (MSA)
Brady and colleagues (2008) [43] created estimates of PWID
population prevalence for the same 96 Metropolitan Statistical
Areas (MSAs) that are studied here for 1992–2002. These data
indicated an overall decreasing trend in prevalence across the 96
MSAs until 2000, after which there was a slight increase; they also
identified substantial variation across MSAs in these trends [43].
Analyses have also discovered substantial variation in PWID
trends across subpopulations over time. Cooper and colleagues
(2008) [44] reported that non-Hispanic black PWID prevalence
declined from a median of 279 injectors per 10,000 adults in 1992
to 156 injectors per 10,000 adults in 2002. PWID prevalence for
non-Hispanic white adults remained relatively flat over time
(median values ranged between 86 and 97 injectors per 10,000
adults). Hispanic PWID prevalence rate also declined significantly
(1992 mean=192, median= 133; 2002 mean=144, median= 93)
[45].
Chatterjee and colleagues (2011) [46] found the mean
proportion of young PWID (ages 15–29) across MSAs increased
by almost 20%, from a mean of 103 per 10,000 in 1996 to 122 per
10,000 in 2002. Young PWID increased significantly in nearly
thirty-four separate MSAs, and declined significantly in approx-
imately ten.
In this paper, we revise and extend the PWID estimates for the
period 1992–2007 for both the overall PWID population and for
specific subpopulations of PWIDs. PWID subpopulations are
defined by: (1) sex (male and female); (2) age (youth 15–29 years
and older 30–64 years); and (3) race/ethnicity (non-Hispanic
white, non-Hispanic black, and Hispanic). Our estimates capture
current injectors as opposed to ever-injected (i.e., since 1977).
Measures and estimates of current injectors provide valuable
information for needs assessment, public health program planning,
program evaluation, and development of public policy to reduce
harm among PWID. Current estimates among PWID are of
particular importance for linking PWID to services and care.
In the following sections, we describe our method of estimating
PWID prevalence rates for adults living in large MSAs each year
between 1992 and 2007 both overall and for specific subpopula-
tions; validate these estimates; and report temporal and spatial
variations in these estimates. Lastly, we close with a discussion of
the PWID estimation methods and limitations, and discuss
possible causes and consequences of the observed trends in PWID
and PWID subpopulations.
Data and Methods Overview
In this analysis, we update and amend previously published
methods of estimating current PWID prevalence among adult
residents of large U.S. MSAs [43,47]. For each MSA, four
component sets of estimates are calculated. Each of these allocates
a proportion of the national total of PWID to an MSA. The first
set of estimates represents the MSAs proportion of the national
total of PWID based on the proportion of HIV Counseling and
Testing (Centers for Disease Control and Prevention [CDC] HIV
Counseling and Testing Services database [CTS] [48]) events in
which PWID were clients. The second uses the MSAs proportion
of the national total of PWID in drug abuse treatment in the
Uniform Facility Data Set (UFDS) [49,50,51] and Treatment
Entry Data System (TEDS) from the Substance Abuse and Mental
Health Service Administration (SAMHSA) [52]. These estimates
both depend on the extent to which services are provided for
PWID–which can vary by budgetary, siting and other decisions
made by funders or service providers. They thus need to be
balanced by estimates that might be higher where under-servicing
is particularly high. We accomplish this by using a third
component estimate reflecting: (1) the extent to which HIV-
positive PWID develop new AIDS diagnoses (data from CDC’s
National HIV Surveillance System on AIDS diagnoses among
PWID) [53]; and (2) adjusting this with our previous estimates of
HIV prevalence among PWID in the MSA [54]. A fourth estimate
is based on extrapolation of estimates from earlier years to more
recent years [55,56], creating four distinct series of estimates of the
number of injectors in each MSA and year. The final estimates are
the result of smoothing each U.S. apportioned data series over
time using loess regression and taking the mean value of the four
series as a best estimate of PWID for that MSA and year.
In order to compute MSA-level estimates from the national
estimates of PWID for each year, we used multiplier methods to
allocate the data. In the past, such methods have been widely used
to estimate the numbers of global or local problem drug-using
populations [37,56,57]. National estimates were attributed to
MSAs using the four data series discussed above (Figure 1). As in
Friedman et al (2004) [55] and Brady et al (2008) [43], we
hypothesized that apportioning the national number of PWID to
each MSA using different data sources helps to balance biases and
offset potential limitations of individual datasets. For example,
increases in drug treatment funding and treatment slots for PWID
could make it appear as if the number of PWID was increasing. By
combining our series measures, some of which are either not
subject to service bias or inversely related to services, we mitigate
such service bias effects.
The resulting estimates were smoothed and averaged to create a
PWID-specific estimate for each MSA and year. These MSA
estimates were validated using yearly cross-sectional correlations
with variables theoretically related to drug injection (i.e.,
unemployment, HCV mortality, and drug-poisoning mortality).
Concordance between these constructs and our estimates lends
credence to the validity of our estimates [43]. Our methods and
steps used to create national and MSA-specific PWID prevalence
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estimates from 1992 to 2007 are described below and are outlined
in Figure 1.
Lastly, we estimate PWID prevalence rates for three sets of
subpopulations: (1) sex (male and female); (2) age (youth ages 15–
29 years, older ages 30–64); and (3) race/ethnicity (non-Hispanic
white, non-Hispanic black, and Hispanic). Our subpopulation
estimates use a different set of procedures than that of the overall
PWID estimates. Here, to estimate subpopulation prevalence we
multiplied yearly estimates of the proportion of PWID who were in
the subpopulation in each MSA by yearly estimates of the total
number of PWID in each MSA, and divided by their respective
populations. The proportions of PWID who were in each
subpopulation were estimated by combining three data series
based on indicators of PWID use of health services and AIDS
surveillance data. The PWID subpopulations are combined by
using predicted values from a binomial mixed-effects regression to
produce MSA-specific rates. The PWID subpopulation estimates
are also validated using yearly cross-sectional correlations with
variables theoretically related to drug injection. Figure 2 includes a
flow chart of procedures for estimating PWID subpopulations
prevalence.
Metropolitan Statistical Areas: Unit of Analysis
This analysis estimates the annual number of current PWID in
96 MSAs for each year from 1992 to 2007. The June 30, 1993
Office of Management and Budget [47] MSA definitions, which
were based on the application of 1993 metropolitan area standards
to 1990 census data, were used in these analyses, except in New
England, where we instead used New England County Metropol-
itan Areas (NECMA) definitions [47,58].
MSAs are defined to represent a central population in a large
city and surrounding urban and suburban areas which have strong
economic and social ties [47,58]. The MSA is a particularly useful
geographic unit for studying PWID and HIV epidemiology among
PWID for several reasons. Drug distribution networks often
parallel networks of distribution of legal commodities [55,59]. In
addition, social networks of drug users often include individuals
from inside and outside central cities, but include individuals from
multiple MSAs less often [60,61]. Most importantly, MSAs are
large enough to have discrete HIV outbreaks and unique data on
drug use and HIV while still being small enough to be sensitive to
relatively small differences in HIV outbreaks and small changes in
social and economic contexts and in population characteristics
over time.
Step 1: Estimating the Number of PWID in the United
States Annually from 1992 to 2007
We analyzed three data series (described below) to estimate the
number of PWID nationwide for each year of the study period.
Our first step was to create an index for each data series by
dividing the number of PWID in the U.S. for that year and the
data series by the average number of PWID over the study period
for that series. Indices serve as a way to compare values of a
variable over time by relating each value in a time series to a
reference or standard value. For each year, index values were
averaged across data sources to create an overall index for each
year. The first set of national PWID estimates was the ratio of the
overall index in a given year to that in 1992 multiplied by
Holmberg’s 1992 estimate of the number of PWID [56]. The
second set of estimates was the ratio of the overall index in a given
year to that in 1998, multiplied by Friedman’s 1998 estimates [55].
Figure 1. Flowchart of Methods for Estimating People Who Inject Drugs in 96 Metropolitan Areas from 1992–2007.
doi:10.1371/journal.pone.0064789.g001
Population Prevalence of People Who Inject Drugs
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e64789
The final set of national estimates was created by averaging the
first and second set of approximations (Figure 1).
To create the national estimates for PWID for 1992–2007, we
utilized three different data series to estimate the number of PWID
nationwide from 1992–2007: (1) data from the CDC’s CTS which
monitors the utilization of counseling and testing services in CDC-
supported sites; [48,62]; and (2) the SAMHSA’s TEDS [52] to
determine the number of injectors entering treatment nationwide
each year of the study period; and (3) the Uniform Crime
Reporting Program County-Level Detailed Arrest and Offense
time series data, produced and distributed by Inter-university
Consortium for Political and Social Research (ICPSR) [63], to
calculate the number of arrests between 1992 and 2007 for
possession of opium, cocaine, and their derivatives (i.e., ‘‘hard’’
drug arrests). These data include arrests of non-injecting users and
of PWID.
In 2005–07, CTS data reported lower national testing numbers
which may be attributable to fewer health departments reporting
test level data for those years based on a new reporting form
starting in 2005. In 1999–2004 approximately 48–50 health
departments were reporting test level data whereas those numbers
have been decreasing 2005 (43), 2006 (34), 2007 (31). To correct
for this, we predict US CTS data for year 2005–2007 using a
quadratic polynomial model based on year and using years 1992–
2004.
In creating U.S annual PWID estimates, we utilized the method
of Brady et al [43] by first creating index values [64] for each of
the three data series described above. We use the average value for
the 16 years of our study period as our reference value for each
data series. For example, the index value for TEDS, in a given
year, is the number of PWID entering treatment in that year
divided by the average number of PWID entering treatment
1992–2007, multiplied by 100. The indices for the three series
were averaged across data sources to create an overall index for
each year which was less sensitive to year-to-year fluctuation from
each data source.
We then multiplied the index by (1) Holmberg’s 1992 PWID
estimate [56] and by (2) Friedman et al’s 1998 PWID estimate
[55], thus creating two sets of national PWID estimates for each
year of the study period. The final set of national estimates was
created by averaging the Holmberg-based and Friedman-based
ratios to calculate a ‘‘best’’ national PWID estimate (Figure 3).
Step 2: Calculating MSA-Specific Estimates of PWID: 1992
to 2007
As in Brady et al. (2008) [43] and Friedman et al. (2004) [55],
multiplier techniques were utilized to allocate national estimates of
PWID to each MSA. To estimate the prevalence of PWID in each
MSA, we calculated the number of PWID in each MSA and year
from each of four data series as described in Table 1. We refer to
Figure 2. Flowchart of Methods for Estimating People Who Inject Drugs Prevalence for Subpopulations in 96 MSAs, 1992–2007.
doi:10.1371/journal.pone.0064789.g002
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these data series as the ‘‘component series’’; the number of PWID
from a given component series, MSA and year as ‘‘component
series counts’’; and MSA-level estimates derived from a given
component series and the national estimates as its ‘‘component
estimate.’’ Each component estimate required a unique method-
ological approach.
CTS data components estimates. We use the following
formula to apportion the national PWID estimate for each year to
each MSA for the CTS and drug treatment-based data series
independently.






Ait – Component estimate for an MSA i in year t;
Bit – Component series count for an MSA i in year t per 10,000
population 15–64 years;
IUSt – Estimated number of PWID for the entire U.S. in year t;
CUSt – Component series count for the entire U.S. in year t;
RUSt – Ratio of the estimated number of U.S. injectors to the
component series count for U.S. in year t.
For the first component estimate using CTS data [48] we
applied Formula 1 to allocate the number of people tested for HIV
who identified injection drug use as a risk factor in the CDC’s HIV
CTS data. These testing data also included men who have sex
with men (MSM) and who also reported injecting drugs. For each
year we allocated our national PWID estimate to MSAs by taking
the number of PWID tested for HIV per population aged 15–64
years in the MSA times 10,000 and multiplying this number by the
ratio of the national number of PWID to the number of PWID
tested in the U.S.
Drug treatment data component estimates. Identical
methods were used to create estimates based on drug treatment.
Our second component estimate uses the drug treatment data
(SAMSHA’s UFDS/N-SSATS [49,50,51] and TEDS [52]); we
utilize Formula 1, and for each year, our national PWID estimates
were allocated by taking the number of drug users (UFDS/N-
SSATS) multiplied by the proportion of drug users entering
treatment who injected in that MSA (TEDS) and multiplying this
number by the ratio of the national number of PWID to the
number of drug users in treatment in the U.S. (UFDS/N-SSATS).
AIDS diagnoses adjusted for HIV prevalence. Our third
component series was created using data on the yearly number of
incident AIDS case diagnoses [53,65] with transmission categories
noted as injection drug use or both male-to-male sexual contact
and injection drug use. We have adapted these data to use time-
varying estimates of HIV prevalence rates in each MSA and in the
US as a whole (Appendix S1 describes in detail our methods for
estimating time-varying HIV prevalence rates in each MSA and in
the US as a whole among PWID for years 1992–2008). We base
Figure 3. National Estimates of People Who Inject Drugs, by Index, 1992–2007.
doi:10.1371/journal.pone.0064789.g003
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our AIDS component estimates on the assumption that there is a
constant proportionality of HIV prevalence rate five years before
to the percent of PWID who are HIV-positive and who develop
AIDS. We use a five-year lag because an untreated person takes
approximately 5–10 years from HIV infection to progress to AIDS
infection [65,66,67], and because using a lag larger than five
would cut into the number of years for which we can make an
adjustment. The assumption of constant proportionality is
counterfactual but benign for this purpose. It is benign to the
extent that a large part of the variation of HIV infection and
progression to AIDS is due to poor access to Highly Active
Antiretroviral Treatment (HAART) and utilization of HIV
counseling and testing or drug treatment services for PWID–
which implies that errors in this adjustment should counter-
balance errors in estimates due to changing service-levels and
service encounter biases. Formula 2a thus assumes that each
MSA’s share of the total number of injection-related AIDS cases
diagnosed nationwide in year t equals that MSA’s share of the total
number of injection-related HIV cases nationwide in year t 25.
Iit=IUSt~Ait=AUSt adjusted forHIVprevalence
rates in year t{5
ð2aÞ
Inserting the adjustment into equation 2a, we get:
Iit=IUSt~(Ait=Hit5)=(AUSt=HUSt5) ð2bÞ
where
Iit – Estimated number of PWID in the MSA i in year t;
IUSt – Estimated number of PWID in the U.S. in year t;
Ait – Number of AIDS cases diagnosed in PWID in the MSA i
in year t;
AUSt – Number of AIDS cases diagnosed in PWID in the U.S.
in year t;
Hit5– Estimated number of HIV cases among PWID in the
MSA i in year t25;
HUSt5– Estimated number of HIV cases among PWID in the
U.S. in year t25.
Solving equation 2b for the number of PWID in an MSA in a
given year t gives us equation 2c.
Iit~IUSt  (Ait5=Hit5)=(AUSt5=HUSt5) ð2cÞ
Lastly, to complete the AIDS adjusted component estimate, for
years 1992–1996, we use data calculated from Brady et al (2008)
[39].
Previous Estimate Component Series. Our fourth and
final component estimate updates and extends the 1992–2002
Holmberg-Friedman PWID estimation series for years 2003–2007.
We predict data for year 2003–2007 using a polynomial regression
model using quadratic and cubic measure of time based on year
and using years 1992–2002. The Holmberg-Friedman PWID
1992–2002 estimate series were calculated by Brady and
colleagues [43] by interpolating yearly MSA-specific PWID
estimates based on Holmberg’s 1992 [56] and Friedman’s 1998
[55] estimates, and then extrapolating the number of PWID in
each year from 1999–2002 by using the yearly change in PWID
between 1992 and 1998 (see Brady et al (2008) for a detailed
discussion of the Holmberg-Friedman PWID estimate series
calculation).
Excluding outliers, imputing missing values, and
combining component estimates to create overall
metropolitan statistical area–specific people who inject
drug estimates. We correct for missing values in each data
series when calculating the PWID component estimates. Missing
values occurred for a variety of reasons, although most arose
because the source database obtained by the project lacked data
on either CTS HIV testing or drug treatment entry data for
specific MSAs and years under study. Thus, missing data were
considered under the following circumstances:
1. In some instances, missingness arose simply because data were
not collected in some of the MSAs and for years during the
study period (e.g., Little Rock, AR; Honolulu, HI and San
Juan, PR MSAs do not report CTS data to the CDC; Hartford,
CT; New Haven, CT; Phoenix-Mesa, AZ and Tucson, AZ
drug treatment centers do not report mode-of-administration,
Table 1. Description of the four databases utilized to estimate People Who Inject Drugs.
Database Description and Characteristics
Counseling & Testing Services Individual reports on injecting at CDC HIV testing sites. Data are a count of tests not unique
individuals, and thus can count an individual more than once a year
Drug Treatment Services (1) UFDS/N-SSATS collects facility-level data annually from all privately and publicly funded substance
abuse treatment facilities in the country, as well as from state-administered facilities; data reflect
program services on October 1 of each year.
(2) TEDS - The Substance Abuse and Mental Health Services Administration, Treatment Episode Data
Set (TEDS) records data on admissions to public and private drug treatment programs that receive
state funds, certificates, or licenses. An individual who enters drug treatment twice or more in a year is
counted as two or more independent cases, which inflates the annual treatment entries.
AIDS Diagnoses AIDS case data give the number of individuals diagnosed with AIDS as reported to CDC by state and
local health departments through the CDC’s National HIV Surveillance System [51]. These data report
yearly number of incident AIDS diagnoses with transmission categories noted as injection drug use or
both male-to-male sexual contact and injection drug use.
Estimates from previously published data This series utilizes previously published estimates by Holmberg from 1992 [44] and by Friedman for
1998 [43] for PWID per population aged 15–64 years.1
1These time series estimates of PWID are partially derived from past studies, their methods are described in detail elsewhere (see Holmberg 1993; Friedman et al 2004;
or Brady et al, 2008).
doi:10.1371/journal.pone.0064789.t001
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and Gary, IN and San Juan, PR do not report drug treatment
admissions to SAMSHA);
2. Data were set to missing if there were unexpectedly high or low
values (i.e., more than twice, or less than half, the magnitude in
values of both of the adjacent years), suggesting a possible error
in the data source. This accounted for 78 observations in
CDC’s CTS data and five observations in the drug treatment
data set of the overall 1,536 observations; and
3. Data were set to missing based on the exclusion criteria. We
applied plausible bounds to the four component series and any
values falling outside set bounds were set to missing and
imputed. We excluded component estimates that fell outside
the plausible bounds for a value. Component estimates were
bounded between 15 and 696 PWID per 10,000 population
aged 15–64 years. These lower and upper bounds were set by
taking 1/2 of the minimum and twice the maximum number of
PWID per 10,000 population aged 15–64 years from any MSA
estimate from Holmberg’s 1992 and Friedman’s 1998 PWID
estimates for MSAs. The CTS and drug treatment component
series had only minimal data that fell outside the plausible
bounds; and no values from the AIDS component estimate or
the component estimates interpolated and extrapolated from
estimates for 1992 and 1998) fell outside the plausible range.
These exclusion criteria resulted in the exclusion of 127
component estimates: Seventy-nine drug treatment-based
values were excluded because of low values; forty-eight low
values based on counseling and testing were excluded. These
127 values were treated as missing data.
When data were missing for any of these reasons, we imputed a
value for this component equal to the average of the values for the
non-missing components. For this, single linear regression
imputation was used to estimate the predicted value of these
observations. For each component series, missing values were
predicted by the other component series separately. The missing
values were replaced with imputed predicted values for that MSA
based on regression models results for each component series with
non-missing.
Smoothing and averaging component estimates to create
final PWID estimates. The values of each of the component
estimates for each MSA across time were smoothed using loess
regression, which fits curves to noisy data and smoothes data in a
manner similar to computing a weighted moving average on time
series data.
The predicted values of the component estimates resulting from
the loess regressions for each MSA and year were averaged to
create our final estimates (Appendix S2). We chose a smoothing
coefficient, between 0.4 and 1 by intervals of 0.1, for each MSA
based on the smallest AICC1 criterion [68]. Statistical analyses
were performed by using SAS software, version 9.2 [69].
Calculating MSA-Specific PWID Subpopulation
Prevalence: 1992 to 2007
The following sections describe our methods for calculating the
proportion of PWID in three subpopulations across MSAs and
year. We stratify each three subpopulation into specific groups: (1)
sex (male and female); (2) age (youth 15–29 years and older 30–64
years); (3) and race/ethnicity (non-Hispanic white, non-Hispanic
black, and Hispanic). Figure 2 describes our methods and
procedures for calculating the subpopulation prevalence estimates.
We further assess the reliability and validity of both the overall
PWID estimates and PWID subpopulation estimates, and discuss
trend results for both.
Our estimates of MSA-specific subpopulation prevalence for
PWID are built on previous methods and estimates by Cooper
et al, (2008) [44], Pouget et al (2012) [45], and Chatterjee et al,
(2011) [46] although no previous prevalence estimates exist for
men and women who inject drugs. The subpopulation prevalence
estimates utilize our current PWID estimates as described above.
The proportions of PWID who were in each subpopulation were
estimated by combining three data series: (1) CDC CTS [48]; (2)
SAMSHA TEDS [52]; and (3) CDC’s data on PWID diagnosed
with AIDS [53]. The CTS data had missing values for four of the
96 MSAs for the entire study period (Honolulu, HI, Little Rock–
North Little Rock, AR, San Juan-Caguas-Arecibo, PR, and
Springfield, MA). We also excluded existing data for one to six
years from 14 MSAs in CTS in order to avoid proportion
estimates that could be unreliable due to small total numbers of
PWID (fewer than 20). In addition, data on proportions of each
subpopulation were available from at least 86 MSAs in each year
from the TEDS treatment data series. Lastly, AIDS data were not
reported according to racial/ethnic category in some states. This
included two MSAs (Cincinnati, OH–KY–IN and Louisville, KY–
IN) within our study boundaries.
To reduce potential bias due to variation among MSAs in
relative HIV prevalence, we adjusted the proportion of PWID
who were in each subpopulation from the AIDS data (PAIDS) for
HIV prevalence among PWID calculated from CTS data (see
Appendix S1 for adjustment formula). Database-specific estimates
were combined by using predicted values from a binomial mixed-
effects regression to produce MSA-specific rates.
To estimate subpopulation PWID prevalence we multiplied
yearly estimates of the proportion of PWID who were in the
subpopulation (averaging proportions from three data series) in
each MSA by yearly estimates of the total number of PWID in
each MSA, and divided by their respective populations. The age
range used for population subpopulation denominators was 15–
64, except for estimates of young PWID, where the 15–29 age
range is applied. The calculation is summarized below.
Subpopulationij~




Subpopulation ij=Estimated prevalence of PWID among
subpopulation residents in study year i, MSA j in database k.
PropSubpopij=Estimated proportion of PWID who were in the
subpopulation in study year i, MSA j in database k.
PWIDNij=Estimated total number of PWID, aged 15–64, in
study year i, MSA j in database k.
PopSubpopij=Number of residents aged 15–64 who were in the
subpopulation, in study year i, MSA j and database k.
Imputations to estimate missing HIV test results data for
subpopulations estimates. Missing data for calculating sub-
populations estimates were imputed separately. CTS data on the
proportion testing positive for HIV among PWID subpopulations
were incomplete due to inconsistent reporting, removal by the
CDC of testing results from small cells (fewer than 5 positive
results) to protect participant confidentiality, and exclusion of data
on the proportion positive that would have been based on fewer
than 20 PWID.
Missing CTS data for computing the proportion testing positive
for HIV among PWID subpopulations were imputed in two steps.
First, in a binomial mixed-effects regression, values were imputed1
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as a function of: (a) cubic polynomial terms for time; (b) the
proportion of total PWID testing positive for HIV; and (c) the
proportion of PWID tested who were in each subpopulation.
Mixed-effects regressions were performed using the SAS
procedure PROC GLIMMIX [69]. Intercepts and time param-
eters were set to vary randomly using residual pseudo-likelihood
estimation. Next, in MSAs where PWID subpopulation HIV data
were missing, we imputed missing values using predicted values
from a mixed-effects Poisson regression using a cubic polynomial
model of time. We imputed values to fill in missing CTS HIV data
for total PWID in a parallel manner, using year, the proportion of
all CTS clients testing positive for HIV, and the proportion of
CTS clients tested who were PWID as predictors for the mixed-
effects binomial regression. Thirteen MSAs had missing data for
all study years; as a result we replaced missing cells with the
average values as predicted by the binomial regressions.
Averaged proportions of PWID in each
subpopulation. We created a complete data set of the
proportions of PWID who were in each subpopulation from the
three data sources–CTS, TEDS and AIDS (adjusted for HIV
prevalence)–using predicted values from a binomial mixed-effects
regression, with one exception: in the San Juan-Caguas-Arecibo,
PR MSA we assume that all of the PWID were Hispanic because
CTS data were not available, TEDS data were not collected by
race/ethnicity, and AIDS data indicated that few PWID with
AIDS were non-Hispanic).
Data were stacked so that each MSA and year was represented
by as many observations as there were data sources (1, 2, or all 3
sources). The model used all the available data to estimate
parameters, even where some data were missing, under the
assumption that the data were missing at random, conditional on
the observed data. Dummy codes were used to compare data
sources. We used a cubic polynomial model of time to maintain
consistency with procedures used to produce the overall PWID
estimates. Intercepts and time parameters were set to vary
randomly using residual pseudo-likelihood estimation. The result-
ing complete sets of proportions were averaged to create single
yearly estimates of the proportion of PWID who were in each
subpopulation. These proportions were then multiplied by
estimates of the number of total PWID to produce estimates of
the PWID subpopulations. The resulting numbers of PWID in
each subpopulation were divided by each subpopulation, respec-
tively, to produce subpopulation prevalence rates.
Testing Reliability of PWID and PWID Subpopulation
Estimates
To test the reliability of our overall PWID estimates (i.e., the
extent to which our component estimates seem to be capturing the
same underlying construct), we examined the correlation between
each of our component estimates for each year. These correlations
describe the extent to which our component estimates produce
similar results.
To assess the reliability of our subpopulation estimates were
compared the proportions of PWID in each subpopulation across
sources of data. We used CTS, TEDS, and AIDS data for racial/
ethnic subpopulation estimates. For estimating sex and age PWID
subpopulations we used CTS and TEDS data only because AIDS
data showed less consistency and produced weak correlations with
the subpopulation proportions in CTS and TEDS data. As such,
we considered the AIDS data less reliable as a measure for these
specific subpopulations estimates. By definition, young PWID have
less time to become HIV-infected and progress to AIDS, and thus
we expect low correlations because AIDS data among youth are
sparse, reflecting less time-at-risk to develop AIDS among youth.
Additionally, HIV is generally found to be lower among females,
which reflect less stable numbers of AIDS diagnosis [1,70,71].
Testing Validity of PWID and PWID Subpopulation
Estimates
To assess the validity of the overall PWID prevalence estimates,
and the PWID subpopulation estimates we compared these with
mortality related to drug-poisoning and HCV mortality. A
minimum of three deaths was used as a criterion for calculating
subpopulation mortality rates. We do not present HCV mortality
analyses for young PWID since they would have had less time to
develop fatal liver disease caused by HCV acquired by injecting
drugs. Additionally, numerous studies have found that economic
conditions are associated with rates of substance use and/or HIV
prevalence [32,43,54,55,61]. Thus, we further utilize a number of
socioeconomic metropolitan area characteristics, including income
inequality, related to the subsequent prevalence of drug injection
in the population.
Identifying drug-poisoning mortality indicators. We
include drug-poisoning mortality as a key validator due to the
high rates of overdose deaths that occur among drug-using
populations. For example, in the U.S., drug overdose is the second
leading cause of unintentional injury death behind motor vehicle
crashes, but is the leading cause of injury death among persons 35
to 54 years of age [44]. We refer to drug-poisoning mortality as
those deaths that are directly caused by an accidental or
unintentional drug-poisoning death. Since injection drug use
cannot be determined in the multiple causes of death files
[72,73,74,75], for both ICD-9 [72] and ICD-10 [73,74,75] coding,
we included a range of substances that correspond to injection
practices. For the ICD-9, we had included a more expansive list of
substances; however, for ICD-10 coding, we decided to adapt our
coding scheme to include only opioids (heroin, methadone, opium,
other opioids, and other synthetic narcotics), cocaine and
psychostimulants. The motivation for this change was both a
desire to simplify the coding scheme and to reduce inconsistencies
in case definitions inherent in trying to identify overdose deaths
related to injection drug use. Drug-poisoning deaths were included
if the MSA in which the death occurred matched one of our study
MSAs. Our algorithm for drug-related mortality is adapted from
the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) ICD-9 and ICD-10 coding scheme [76,77].
Identifying HCV virus mortality indicators. HCV virus
(HCV) was selected as a validator because it is a blood-borne
infection most commonly transmitted in the U.S. via PWID [78].
The HCV was first identified in 1989 and widespread screening
and testing of the virus began in 1993. Thus the ICD-9 coding
conventions used to identify HCV might result in an underesti-
mation of the contribution of HCV to mortality in the early years
of the study period [79,80,81,82]. We utilize the ICD-10 coding
[73,74,75] scheme to identify HCV mortality, defined as deaths
recorded as either acute (B171) or chronic (B182) HCV [78];
accordingly the correlations values only reflect data from 1999 to
2007.
Studying Temporal Trends
We analyze trends over time for overall PWID prevalence rates
and subpopulation prevalence rates by utilizing mixed-effects
polynomial models with PROC MIXED using linear, quadratic
and cubic terms for time [68]. We centered time at the mid-point
of the study period, year 2000. Nested models were compared
using likelihood ratio tests [69].
Sample and its implications for statistical
analyses. This is a study of 96 MSAs that are the largest
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metropolitan areas in the U.S. Therefore, it was a study of a
population rather than of a sample. This means that there was no
sampling error (although there was measurement error). Statistical
analyses are primarily descriptive rather than inferential. Thus, the
use of p values in this analysis is a guide to the relative
‘‘importance’’, and not the significance of possible associations.
Some researchers conducting studies with similar populations use
P values as a heuristic device to avoid over-interpreting model
parameters [83,84,85] (We refer to these as pseudo-Ps.) Other
analysts would consider the population to be a random sample of
‘‘possible universes’’; under this interpretation, pseudo-Ps have a
probabilistic interpretation.
Results
Reliability and Validity of the PWID and PWID
Subpopulation Prevalence Estimates Reliability and
Validity of the PWID Prevalence Estimates
We assess the reliability of our PWID estimates by comparing
each component series estimate across data sources. Figure 4
presents the correlations across MSAs of the component series
estimates by year for the overall PWID prevalence estimates. In
general, the intercorrelations were moderately strong and mostly
stable over time, which is expected because the component
estimates aim to measure the same underlying construct. As
expected CTS and TEDS component series correlate more
strongly with each other than with AIDS component series, since
counseling and testing, and drug treatment represent services that
can help to prevent HIV infection or delay progression to AIDS
for those who are infected. These was an overall declining
correlation between the drug treatment counseling and testing and
AIDS-based component estimates, and to some extent, between
the counseling and testing and AIDS-based component estimates
which may suggest that the performance of the AIDS adjustment
formula that relates HIV prevalence to AIDS cases deteriorates
over time, or that our estimates are affected by service bias to a
greater extent over time.
Convergent validity was assessed by evaluating if the PWID
prevalence estimates correlated with theoretically relevant predic-
tors, including unemployment, drug-poisoning mortality and
mortality from HCV. Table 2 displays the cross-sectional
correlations between PWID prevalence and theoretical constructs.
Correlations between PWID prevalence and unemployment
varied little over time ranging from 0.42 in 1992 to 0.35 in 2003
where correlations declined starting 2004. Correlations between
PWID prevalence and drug- poisoning mortality held steady over
time ranging from 0.51 in 1992 to 0.40 in 2003– correlations
declined starting 2004. Correlations between PWID prevalence
and HCV mortality were consistent across years, ranging from
0.48 in 1999 to 0.43 in 2007.
Additionally, correlations of the estimate of the prevalence of
PWID with theoretically related indicators, such as percent living
in poverty and income inequality were analyzed. The correlations
between percent in poverty in 1990 and our PWID estimates per
10,000 population in 1992; between poverty in 2000 and our
PWID estimates per 10,000 population in 2000 were 0.33 and
0.36 respectively; and finally between income inequality 1990 and
2000 and our 1992 and 2000 PWID estimates were 0.24 and 0.23,
respectively (each of these is significant at p = 0.05 level). This
suggests that for the given years our estimates were similarly
accurate to those estimates presented by Brady and colleagues
(2008) [43].
Reliability and Validity of the PWID of Subpopulation
Estimates
Pearson correlations values for the subpopulation estimates are
presented in Table 3. Reliability analysis on the subpopulation
proportions among the data series showed good consistency for
most comparisons as well. CTS and TEDS proportions were
moderately correlated for young PWID and for male PWID, and
correlated somewhat less for female PWID. For all three racial/
ethnic groups, CTS and TEDS proportion data correlated more
strongly with each other than with AIDS proportions.
Figure 4. Intercorrelations between Component Series Estimates, 1992–2007.
doi:10.1371/journal.pone.0064789.g004
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Table 2. PWID Validity: Pearson correlations between PWID prevalence estimates and theoretically related constructs over time.




1992 0.42** – – 0.51**
1993 0.54** – – 0.61**
1994 0.50** 0.44** – 0.51**
1995 0.57** 0.54** – 0.58**
1996 0.56** 0.55** – 0.63**
1997 0.54** 0.57** – 0.60**
1998 0.54** 0.55** – 0.54**
1999
1 0.50** 0.53** 0.48** 0.44**
2000 0.47** 0.51** 0.46** 0.40**
2001 0.43** 0.47** 0.52** 0.39**
2002 0.38** 0.43** 0.51** 0.34**
2003 0.35** 0.37** 0.51** 0.40**
2004 0.28** 0.35** 0.45** 0.25*
2005 0.23* 0.33** 0.41** 0.24*
2006 0.21* 0.28* 0.40** 0.27*
2007 0.18 0.23* 0.43** 0.29*
**pseudo- p,0.001;
*pseudo -p,0.05.
1ICD-10 implemented in 1999:
2ICD-10 codes for HCV are more accurate so earlier data are not reported;
32001 California MSAS set to missing due to inaccurate reporting.
NOTE: Construct variables are calculated as per 10, 000 population.
doi:10.1371/journal.pone.0064789.t002
Table 3. PWID Subpopulation Reliability: Pearson correlations between proportions estimated among CTS, TEDS, and AIDS data
adjusted for HIV prevalence based on CTS test results.
Non-Hispanic White Non-Hispanic Black Hispanic Female
Young
(15–29)
Year C-T1 C-A2 T-A3 C-T1 C-A2 T-A3 C-T1 C-A2 T-A3 C-T1 C-T1
1992 0.68 0.51 0.35 0.76 0.60 0.56 0.92 0.72 0.69 0.36 0.49
1993 0.59 0.45 0.33 0.70 0.56 0.61 0.92 0.83 0.79 0.51 0.54
1994 0.64 0.62 0.47 0.73 0.61 0.57 0.92 0.89 0.85 0.40 0.27
1995 0.69 0.55 0.44 0.84 0.64 0.61 0.90 0.90 0.81 0.36 0.35
1996 0.71 0.58 0.36 0.81 0.61 0.52 0.91 0.78 0.85 0.14 0.31
1997 0.74 0.51 0.29 0.82 0.54 0.57 0.91 0.84 0.87 0.31 0.46
1998 0.77 0.56 0.37 0.83 0.55 0.49 0.91 0.82 0.88 0.26 0.64
1999 0.68 0.51 0.38 0.74 0.57 0.46 0.89 0.77 0.79 0.21 0.62
2000 0.60 0.49 0.36 0.77 0.51 0.47 0.89 0.82 0.82 0.20 0.63
2001 0.62 0.43 0.27 0.72 0.61 0.45 0.90 0.79 0.69 0.15 0.52
2002 0.62 0.44 0.22 0.72 0.46 0.21 0.89 0.80 0.74 0.44 0.55
2003 0.68 0.49 0.32 0.69 0.51 0.41 0.88 0.75 0.76 0.55 0.51
2004 0.74 0.46 0.39 0.80 0.60 0.49 0.92 0.85 0.82 0.49 0.45
2005 0.74 0.29 0.24 0.75 0.45 0.48 0.93 0.76 0.73 0.39 0.42
2006 0.67 0.41 0.23 0.58 0.38 0.39 0.88 0.77 0.73 0.25 0.43
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Female and male PWID proportions in CTS and TEDS data
may not as accurately represent the proportion of females and
males among PWID in the MSA populations relative to
proportions for the other subpopulations. Weak correlations
found for female PWID subpopulation may reflect the fact that
female PWID are much more likely to be stigmatized by society
than their male counterparts because drug use violates social
norms of behavior as it diverges from the traditional expecta-
tions of women as nurturers of families [86, 87). As such, female
PWID may be more inclined to conceal injecting behavior and
hesitant to utilize counseling and testing or drug treatment
services [88,89,90,91,92].
Subpopulation validity was assessed by comparing subpopula-
tion PWID prevalence rates with rates of drug-poisoning deaths
and HCV deaths series showed moderate to strong associations for
most comparisons (Table 4). Correlations with HCV deaths begin
in 1999, when ICD-10 implemented explicit coding for HCV.
Across subpopulations, correlations between PWID rates and
drug-poisoning deaths were higher in earlier years. Correlations
averaged 0.52 for drug-poisoning deaths from 1992–1999, and
0.35 for 2000–2007. Correlations with HCV deaths were 0.30 or
above for all subpopulations in all years, averaging 0.50 across
subpopulations. Correlations with PWID subpopulations and
drug-poisoning deaths generally were reduced over time. Some
values were below 0.20 for Hispanic and male subpopulations in
some years. We conjecture that the downward trend in these
correlations may reflect an increase in the contribution of non-
injecting opioid analgesic users to drug-poisoning deaths over the
study period [93].
Trends in PWID Prevalence and PWID Subpopulation
Prevalence Estimates
Appendix S2 shows the estimates of the number of PWID per
10,000 population aged 15–64 years for each of the 96 largest
MSAs in the US for each year from 1992 to 2007. Mean PWID
prevalence rates and standard deviations are presented in Table 5.
Overall, the number of PWID per 10,000 persons aged 15–64
years varied from 31 to 345 across MSAs, median 104.4 (mean
127.4; standard deviation 66.7; percentile range 76–162) in 1992
and from 34 to 324 across MSAs, median 91.5 (mean 103.6;
standard deviation 56.4; percentile range 61–125 ) in 2007
indicating an overall decline in PWID prevalence across MSAs.
Figure 5 shows the overall trajectory of the PWID prevalence
rates based on the multilevel model. Trend analysis of the overall
results is consistent with a decline in the early study period,
followed by an increase in 2000–02, and then remaining stable
thereafter over time. On average there has been very little change
since 2002 (mean 105.0) to 2007 (mean 103.6). Overall, across the
96 MSAs the mean PWID prevalence mostly decreased during our
study period, as did the dispersion of estimates over time.
Trend analysis results for the overall PWID prevalence are in
Table 6. The linear model indicates the average number of PWID
across MSAs was about 110 PWID per 10,000 population age 15–
64 years in year 2000 where each year from 2000, the average
number of PWID across MSAs declined slightly by about 1.4 per
10,000 population. Quadratic and cubic terms are also presented.
Overall linear and quadratic terms for PWID were significant; the
somewhat smaller linear decline was offset over time by the
quadratic term. Although the cubic term in Model 3 was not
significant, it significantly improved the fit of the model. All models
indicate a decline in PWID prevalence, increasing in years 2000–
02; thereafter, the trend indicates our PWID prevalence rates
Table 4. PWID Subpopulation Validity: Pearson correlations between subpopulation PWID prevalence estimates and theoretically
related constructs over time.
Non-Hispanic
White Non-Hispanic Black Hispanic Male Female
Young
(15–29) Old (30–64)
Year DP1 HCV2 DP1 HCV2 DP1 HCV2 DP1 HCV2 DP1 HCV2 DP1 DP1 HCV2
1992 0.65 – 0.51 – 0.48 – 0.45 – 0.44 – 0.34 0.53 –
1993 0.71 – 0.60 – 0.48 – 0.54 – 0.54 – 0.41 0.61 –
1994 0.62 – 0.61 – 0.51 – 0.46 – 0.29 – 0.47 0.46 –
1995 0.72 – 0.63 – 0.63 – 0.55 – 0.42 – 0.40 0.54 –
1996 0.71 – 0.70 – 0.38 – 0.55 – 0.64 – 0.33 0.60 –
1997 0.70 – 0.72 – 0.64 – 0.56 – 0.46 – 0.55 0.55 –
1998 0.67 – 0.50 – 0.33 – 0.48 – 0.53 – 0.47 0.53 –
1999 0.58 0.56 0.46 0.66 0.33 0.66 0.35 0.43 0.49 0.45 0.44 0.44 0.48
2000 0.54 0.53 0.60 0.60 0.39 0.61 0.32 0.36 0.42 0.45 0.33 0.40 0.49
2001 0.40 0.58 0.23 0.56 0.27 0.80 0.21 0.47 0.31 0.35 0.42 0.22 0.55
2002 0.45 0.56 0.51 0.70 0.28 0.53 0.26 0.41 0.42 0.57 0.27 0.38 0.53
2003 0.51 0.60 0.46 0.41 0.38 0.64 0.36 0.45 0.34 0.38 0.42 0.41 0.57
2004 0.43 0.43 0.40 0.62 20.04 0.33 0.15 0.42 0.33 0.38 0.36 0.28 0.49
2005 0.34 0.50 0.61 0.60 0.23 0.54 0.19 0.33 0.29 0.42 0.36 0.23 0.44
2006 0.40 0.48 0.46 0.52 0.22 0.47 0.22 0.33 0.37 0.37 0.36 0.30 0.52
2007 0.43 0.55 0.53 0.50 0.25 0.57 0.24 0.32 0.36 0.52 0.34 0.30 0.52
1Drug Poisoning Deaths;
2HCV Deaths (beginning in 1999).
doi:10.1371/journal.pone.0064789.t004
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stabilize after 2002 and vary little through the end of the study
period.
We calculated percent change values of the earliest (1992–1994)
and latest (2005–2007) 3 years of data. MSAs that experienced
increased rates in PWID prevalence reside mainly in the northeast
(Baltimore, MD; Springfield, MA; Boston, MA–NH; Providence–
Fall River–Warwick, RI–MA; Harrisburg–Lebanon–Carlisle, PA).
Sarasota–Bradenton, FL; Stockton–Lodi, CA; Youngstown–War-
ren, OH; Salt Lake City–Ogden, UT; Tulsa, OK MSAs also
experienced increases in PWID prevalence rates over time.





Black Hispanic Male Female
Young (15–
29) Old (30–64)
Year Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
1992 127.38 (66.73) 96.51 (62.85) 337.03 (191.43) 183.74 (184.07) 170.47 (92.46) 85.28 (47.63) 101.64 (62.00) 142.47 (73.64)
1993 119.61 (64.68) 90.89 (60.33) 310.38 (192.55) 169.86 (173.09) 158.56 (85.24) 81.77 (48.72) 93.58 (55.89) 133.78 (73.68)
1994 121.63 (60.95) 92.30 (57.02) 300.98 (164.69) 166.51 (176.26) 160.84 (82.43) 83.93 (45.44) 94.91 (54.14) 135.35 (68.59)
1995 114.87 (59.83) 87.35 (54.32) 276.32 (167.84) 156.31 (169.20) 150.77 (78.23) 80.67 (46.12) 90.57 (50.92) 127.44 (69.49)
1996 112.61 (57.99) 85.96 (52.10) 259.71 (159.26) 149.84 (166.52) 147.19 (75.69) 80.01 (45.05) 90.50 (49.50) 124.38 (68.17)
1997 110.49 (56.89) 84.82 (50.67) 244.05 (154.40) 144.44 (165.07) 143.91 (74.22) 79.31 (44.41) 91.32 (49.15) 121.32 (67.60)
1998 108.95 (56.47) 84.32 (50.30) 230.87 (153.89) 139.94 (163.30) 141.49 (73.70) 78.90 (44.26) 93.35 (50.17) 118.67 (67.54)
1999 110.80 (56.23) 87.09 (52.12) 223.61 (147.42) 137.84 (163.44) 143.42 (73.56) 80.86 (44.38) 99.35 (53.69) 119.12 (66.76)
2000 106.71 (56.02) 84.57 (50.75) 210.75 (162.29) 132.05 (157.20) 137.87 (73.58) 78.32 (43.94) 100.38 (54.76) 113.10 (66.90)
2001 109.95 (57.16) 88.82 (54.78) 209.87 (168.06) 131.53 (155.33) 141.48 (74.50) 81.30 (45.53) 108.82 (59.72) 114.26 (67.77)
2002 105.02 (55.64) 85.31 (51.14) 198.49 (177.16) 126.82 (151.29) 135.20 (73.67) 77.59 (43.33) 108.30 (58.75) 107.09 (65.82)
2003 104.56 (55.70) 86.15 (51.44) 195.92 (185.83) 125.01 (148.72) 134.55 (74.15) 77.17 (42.96) 111.53 (60.07) 104.38 (65.58)
2004 104.36 (55.83) 87.26 (51.82) 194.94 (192.54) 123.61 (145.84) 134.16 (74.72) 76.79 (42.56) 113.96 (61.00) 101.88 (65.64)
2005 104.08 (55.78) 88.50 (52.33) 196.03 (198.56) 121.52 (140.53) 133.67 (74.85) 76.14 (42.04) 115.19 (61.29) 99.10 (65.47)
2006 103.89 (55.96) 89.71 (53.02) 200.18 (208.74) 119.13 (133.70) 133.33 (75.22) 75.36 (41.62) 124.62 (66.06) 96.20 (65.34)
2007 103.65 (56.36) 90.88 (54.18) 209.69 (229.77) 117.31 (127.69) 132.94 (75.82) 74.30 (41.33) 126.67 (68.20) 92.89 (65.24)
doi:10.1371/journal.pone.0064789.t005
Figure 5. People Who Inject Drugs Prevalence Rates per 10,000 population: PWID Total and Subpopulations, 1992–2007.
doi:10.1371/journal.pone.0064789.g005
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Table 7 shows the results of test for trends over time for each
subpopulation and are also graphically displayed in Figure 5. The
intercept column represents the modeled subpopulation PWID
prevalence rate in the year 2000. All intercepts were significantly
different from zero. For non-Hispanic white, only the quadratic
term for time was significant, in the positive direction, reflecting a
small increase since 2000 (7.5% in total, or an average of 1.1% per
year). For the non-Hispanic black subpopulation, the linear and
quadratic terms were significant; the strong linear decline seen in
the early 1990s was offset over time by the smaller quadratic term,
reflecting an increase in each year since 2004 (0.6% in 2005, 2.1%
in 2006 and 4.8% in 2007). For the Hispanic subpopulation, linear
and quadratic terms were also significant; the somewhat smaller
linear decline was also offset over time by the quadratic term,
averaging a yearly decline of 4.7% in 1993–1997, 2.6% in 1998–
2002, and 1.5% in 2003–2007. For the male subgroup, linear and
quadratic terms were also significant, with a more modest linear
decline offset by the quadratic term, reflecting an average yearly
decline of 2.6% in 1992–2000, and 0.5% in 2001–2007. For the
female subpopulation, no time effects were significant.
Overall, the number of PWID per 10,000 persons aged 15–64
years varied from 31 to 345 across MSAs in 1992 (mean 127.4)
and from 34 to 324 across MSAs in 2007 (mean 103.7). Trend
analysis indicates that declines during the early period (1992–
2002) leveled off, and rates were relatively stable in 2003–2007.
Mean rates for non-Hispanic black PWID were the highest of all
racial/ethnic groups in 1992 (337.0). After an early steep decline in
the mean, non-Hispanic black PWID prevalence leveled off in
2000, and on average rates increased after 2005. Rates for non-
Hispanic whites increased on average since 2003, although the
rate was only about half that of non-Hispanic blacks. Hispanic
PWID prevalence, in contrast, has consistently declined, although
the decline has slowed across time. Mean male PWID prevalence
shows a decline that decreased over time. Mean female prevalence
shows no clear trend over time, although mean values since 2000
are somewhat lower than those before 2000.
Most notably, our results indicate an overall increasing trend in
young PWID. For the young subpopulation, linear, quadratic and
cubic terms were significant; positive linear and quadratic
increases were offset with a negative cubic term over time,
reflecting a general increase since 1996. After decreasing on
average by 11.0% from 1992–1996 (2.8% per year), the average
rate of young PWID increased by 40.0% from 1996–2006 (3.1%
per year). In contrast, for older PWID, only the linear term was
significant, reflecting a continuous linear decline.
Discussion
Our national estimates indicate that PWID prevalence
remained relatively stable from 1992 to 2007 nationwide. The
overall MSA-level population prevalence of PWID decreased
through the 1990s (as reported in Brady (2008) [43]). Trend
analysis showed an overall decline in the early study period,
followed by an increase in 2000–02; thereafter PWID prevalence
rates remained stable. Trends among subpopulation prevalence
rates varied over time. Importantly, results show a worrisome
trend in young PWID prevalence since HAART was initiated –
the average increase across MSAs for 1996 to 2007 was 35%.
Our validation test showed relatively high to modest correla-
tions between each series of MSA-level component estimates
across years, suggesting that the component estimates measure the
same underlying construct and that our data series support each
other (Figure 4). Multiple sources of data on PWID showed
consistency, and comparisons with data on drug-poisoning
mortality and HCV mortality supported the validity of the
estimates.
PWID prevalence among MSA residents aged 30 and older
closely matched PWID prevalence overall. However, prevalence
was slightly higher among older MSA residents from 1992–2002,
and lower from 2003–2007, reflecting a decreasing average age of
older PWID. Overall, declining PWID prevalence rates among
those 30 and above may stem from increases in overdose and/or
HCV mortality and from age-associated mortality in aging cohorts
of PWIDs. Another explanation for the downward trend in PWID
prevalence in metropolitan areas is that drug users have been
employing alternative modes of drug administration, or discon-
tinue drug use in general. There are numerous reasons to choose
modes of administration other than injection and discontinue use,
including fear of HIV or HCV.
This might be balanced in some MSAs due to declines in HIV-
related mortality due to improved treatments and decreases in
HIV-associated mortality in MSAs where HIV among PWID is
prevalent. Drug treatment programs or other processes may have
led some PWIDs to stop drug use or at least injecting. In addition,
the rising use of methamphetamine and prescription drugs, which
are often administered by means other than injection, may mark a
shift away from injection drug use. Increases in non-injection
opioid use may have influenced changes in PWID prevalence in
contradictory ways, perhaps lead some youth not to inject their
drugs but leading others to start injecting [8].
Prevalence rates for young PWID are consistent with previously
published estimates [46], and confirm and extend the previously
Table 6. PWID prevalence trend analysis with linear,
quadratic and cubic models of time.
Model 1 Model 2 Model 3
Intercept 109.58** 107.08** 107.27**









Note: To minimize potential multicollinearity time is centered at the year 2000.
Model 3 is the best model by likelihood ratio test.
doi:10.1371/journal.pone.0064789.t006
Table 7. PWID subpopulations trend analysis with linear,
quadratic and cubic models of time.
Intercept Linear Quadratic Cubic
Non-Hispanic White 85.17 0.32 0.13** 20.01
Non-Hispanic Black 211.80 28.38** 1.01** 0.02
Hispanic 132.73 23.06** 0.24** 20.02
Male 138.46 21.41** 0.17** 20.02
Female 78.90 20.28 20.01 20.01
Young (15–29) 100.64 3.52** 0.18** 20.03*
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observed increase that began in 1996. There are at least two
potential explanations for this increase. First, young MSA residents
may have avoided injecting in the early 1990s due to the well-
publicized risks of HIV/AIDS, and morbidity and mortality
associated with injecting drugs. Potentially, this reluctance may
have been reduced over time since the HAART era due to HIV
treatment optimism, similar to explanations some have hypothe-
sized for increased sexual risk behavior among MSM [94,95].
Moreover, recent increases in non-medical use of prescription
opioids may have led some new opioid users to inject prescription
opioids or transition to heroin or methamphetamine injecting
[96,97]. A recent study by Jones (In Press) [98], found that over
77% of people using both prescription opioid and heroin in the
past year report initiating a prescription opioid prior to heroin
initiation. Among the three age groups examined in the study, 18–
25 year olds had the highest rate of past year heroin use – of those
in this age category 12.3% also used heroin in the past year, a 95%
increase compared to 2002–2004. Additional studies by Church
et al., (2011) [99] and Stanley et al., (2012) [100] reportedly linked
new HCV infections in young adults to the use of prescription
opioids and transition to heroin or methamphetamine injection.
If young PWID engage in high levels of risk behavior, this could
lead to widespread increases in HIV transmission that could
parallel recent increases in HIV incidence among young MSM.
Young MSM increasingly assume the heaviest burden of HIV
infection, presenting more than half of new infection in 2010 [1,2].
A critical component of risk among young MSM is the intersection
of the HIV epidemic, substance use (which includes both injection
drug use risk and non-injection risks), and unprotected sexual
activity with multiple partners [101,102,103]. The increasing
practice of injecting methamphetamine among MSM leads to
greater risk of HIV, STIs and hepatitis, offering new challenges for
prevention and reducing harm among MSM injectors
[102,103,104].
An early steep decline in non-Hispanic black PWID prevalence
leveled off, and on average, rates increased since 2005. Mean rates
for non-Hispanic black PWID were the highest in 1992 (mean
337.0), and lowest in 2004 (mean 195.0). Although representing
less than 14% of the total population in the US, non-Hispanic
blacks are disproportionate affected by HIV–accounting for 44%
of HIV infection for 2010 [1,2]. Recent increases in non-Hispanic
black PWID prevalence warrant further investigation, given that
the average annual rate of new HIV infection diagnosis per
100,000 population during 2004–2007 was 11.0 for non-Hispanic
black PWID, 4.9 per 100,000 for Hispanic PWID, and 0.9 per
100,000 for non-Hispanic white PWID [1,10]. As such, HIV
infection among PWID subpopulations continues to be a public
health issue – where non-Hispanic blacks are disproportionately
affected by HIV [1,2].
Knowledge of these findings can assist research that investigates
the causes and consequences of increasing PWID prevalence
among subpopulations, including how risk exposures differ among
subpopulations. For example, young injectors may be less aware of
the dangers of injecting drugs and how to reduce their risk, and as
such, more likely to share syringes and drug preparation
equipment increasing their risk of HIV, hepatitis B and C, as
well as fatal overdose and homicide [96,97,98,100,105,106,107].
In contrast, non-Hispanic black injectors are more likely than
other PWID subpopulations to experience drug-related arrests and
incarceration [108,109]. Fear of arrest has been associated with
higher rates of risk behaviors, with difficulty in using prevention
programs, and injection-related infections [110,111,112,113,114].
Resource availability and the allocation of resources can vary
greatly, affecting where and when prevention and treatment
services are implemented. Access to a broad range of compre-
hensive health services, medical care and drug treatment services,
such as those offered at MAT facilities, are fundamental to
achieving and reducing harm among PWID [115,116]. Effective-
ness of MATs may have played a role in the overall decreases in
PWID rates we observed and decreasing HIV transmission rates
among PWID. Provisions of MAT for PWID and PWID
subpopulations remain central to efforts for the prevention and
management of HIV infections and health care among PWID;
however, access and coverage of MAT might not be sufficient in
some U.S. localities, further impacting PWID rates and HIV and
HCV transmission, particularly among young PWID and non-
Hispanic black PWID.
One of the most practical applications of our PWID estimates in
terms of targeting primary and secondary HIV prevention
initiatives would be the computation of population-based HIV
and HVC transmission rates among PWID and subpopulations.
Furthermore, trend data on PWID prevalence and subpopulations
may provide a foundation for the design, implementation and
evaluation of structural interventions and service coverage, such as
the expansion of OTPs and MAT facilities in areas of need
[31,32,117]. Efforts to characterize PWID populations and PWID
subpopulations have been complicated by prejudices about the
stigmatizing nature of injection drug use [118,119]. Prejudice
about drug use, and in particular injection drug use, makes it
difficult to assess the actual numbers of PWID over time and
across geographic areas [36,37,38,39,40,41,42]. Our estimates on
overall PWID population prevalence and PWID subpopulation
prevalence have attempted to correct for this inability to measure
and estimate PWID populations.
Data Source Biases
Data sources were chosen so that biases of the different data
sets, in theory, would cancel one another out [43,55]. For
example, the CTS data and the TEDS data both reflect health
service provision: if funding for health service declines, so will the
number of PWID noted for that data set. In contrast, a high
component estimate based on PWID being diagnosed with AIDS,
in conjunction with low service-based component estimates, may
reflect inadequate services for PWID, such as having poor access
to HAART. It is important that our various component estimates
are not subject to the same biases, so that when they are averaged,
even if one component estimate declines because of funding cuts,
another component estimate will be unaffected by this event or will
be affected in the opposite way.
Limitations
Despite the fact that using different data sources helps to
balance biases, each data series has strengths and weaknesses and
are subject to several limitations. These limitations have been
discussed in detail elsewhere [43,44,45,46,55], and are briefly
reviewed here.
First, with regard to TEDS and UFDS/N-SSATS, during our
study period SAMSHA eliminated questions from UFDS about
the number of PWID in treatment programs after 1998. We
therefore multiplied the proportion of drug users entering
treatment who inject drugs (from TEDS) in each MSA and year
by the total number of drug users in treatment as reported by both
UFDS/N-SSATS. Second, these data sets differ in what they
count: TEDS counts each admission in a given year, so an
individual who enters drug treatment twice or more in a year is
counted as two or more independent cases. In contrast, UFDS/N-
SSATS client count numbers are from a point-prevalence survey–
those in treatment on one specific day. It gives a snapshot of the
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substance abuse treatment system on a given day. Consequently, if
PWID differ from non-PWID in the ratio of admissions to those
remaining in treatment, our estimates will be biased.
Additionally, UFDS/N-SSATS data sets were not available for
1992, 1994, 1999, and 2001. We did not impute UFDS/N-SSATS
for the years 1992, 1994, 1999, and 2001 because we did not
believe there was a need to estimate the variance of the individual
series, as the treatment component estimate would be smoothed
and averaged with the other component estimates. As such, our
final PWID estimates are calculated without using UFDS/N-
SSATS data in the above years.
The counseling and testing data series has several limitations.
First, data only exist where there are publicly funded CDC HIV
counseling and testing sites. Since CTS systems only collect data
from subsets of United States locations where publicly funded
CDC HIV counseling and testing take place our estimates may be
biased to the extent that the demographic distributions of PWIDs
using these sites differ from those at sites that were not included.
For example, the HIV CTS data as a whole are considered to only
represent approximately 10–15% of all HIV tests in the U.S.
[48,120]. Therefore, HIV testing of PWID occurring at a health
maintenance organization or at a blood donation center is not
included in these data and may lead to an underestimation of the
number of PWID. Second, reluctance to identify and report illicit
and otherwise stigmatized behaviors may lead to misclassification
and underreporting of PWID in the counseling and testing data.
Additionally, the counseling and testing data classify injectors as
anyone injecting since 1978, although definitions used to classify
injectors may vary by health department e.g., some people were
classified as PWID if they reported injecting in their lifetimes,
while others were classified as an PWID only if they reported
injecting in the past 30 days, or since the last HIV test [120,121].
This means we may not be capturing recent injectors in this PWID
prevalence measure and that comparability across health depart-
ment jurisdictions may be limited.
Included in our PWID estimate model was an adjustment for
time to the advent of highly active antiretroviral therapies
HAART in 1996. Since then, HAART has become the standard
of care for the treatment of HIV-infected individuals. As HAART
has become more widely used, AIDS researchers have seen an
increase in the time from HIV infection to progression of AIDS,
and an increase in survival time from a diagnosis of AIDS to death
[122,123,124,125]. Thus, as survival time increases prevalence
rates in the research estimates we needed to adjust for this in our
equation. During our study period, access to HAART changed
over time and took time to reach PWID–thus, we assume year of
1996 as a uniform time for which PWID had access to HAART.
To adjust for this in our AIDS component estimation series, we
assume that PWID in all MSAs have equal access to HAART,
starting 1996.
The component series based on the interpolation and extrap-
olation of Holmberg and Friedman’s estimates assumes a linear
change on the log scale for each MSA. The weakness in this
assumption is that the changes in number of PWID may not have
changed linearly (on the log scale) over time in each MSA.
Additionally, this component series is further subject to all the
limitations, biases, and weaknesses that Holmberg and Friedman
highlighted in their papers.
Finally, our PWID estimates do not extend beyond 2007.
Completion of our estimates is based on the availability and
release of secondary data; as such data for producing PWID
estimates beyond 2007 were not readily available. In this paper,
we presented estimates of the prevalence of people who injected in
the last year. As such, these estimates do not provide information
about the frequency of injecting or about risk behaviors among
injectors.
Conclusions
With proper acknowledgement of their limitations, these data
can be used for structural analyses of the correlates and predictors
of the population density of PWID and subpopulations in
metropolitan areas. Specifically, the correlations found between
the PWID estimates and theoretically relevant variables suggest
that further research should be done to determine whether
socioeconomic and health policy affect the population density of
PWID.
These PWID prevalence and subpopulation prevalence esti-
mates can help local agencies plan local drug-related interventions
and policies. For example, where both our broader estimates and
local data suggest that PWID prevalence is steady or rising, local
health departments working together with syringe exchange
programs might intensify outreach efforts targeting this popula-
tion. Our estimates can also be used to measure the extent to
which health systems and social service systems are providing
services to PWID and PWID subpopulations.
For example, before now no adequate data have existed on
patterns of female PWID prevalence over time within geographic
areas. The lack of such prevalence data makes it difficult to assess
whether at a metropolitan area has gender disparities in access to
essential services [126,127]. Thus the sex-specific PWID preva-
lence estimates reported here can inform planning efforts for
health services for female PWIDs, and help design comprehensive
health programs for female PWID. In addition, in the U.S.,
overdose is the most frequent cause of mortality among PWID
[128,129,130] and the second leading cause of accidental injury
death overall [130]. Our PWID prevalence estimates and
subpopulation estimates can deepen our understanding of the
causes of determinants and changes over time in overdoses deaths
and HCV mortality among PWID populations. Finally, with more
young people injecting, drug-related morbidity, including over-
dose, HIV and HCV infection, is likely to increase in this age
group. Funding for harm reduction and other health-related
services targeting young PWID should be increased.
In summary, it is clearly of very high importance to conduct
research to understand what it is about some, but not other, MSAs
that leads to increasing PWID prevalence, and to monitor future
changes in injection by youth and, in general, changes in PWID
prevalence and subpopulation prevalence rates. Our estimates can
be used to inform public health officials about population
vulnerability to future blood-borne epidemics, and will help local
policy makers differentiate why PWID prevalence and subpopu-
lation prevalence varies over time. Additionally, our estimates may
be used in research into how socioeconomic conditions, public
health programs, policies, and other socio-political factors shape
the prevalence of PWID in a population.
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